Pharmacodynamics +<unk>  Site Ki (nM) Species Ref 110 ' 21–532 Human 1,699 5-HT1A 138–230 Human 5-HT2A 0.30–0.43 Human 5-HT2B 5-HT2C 4.5 ' 5-HT3 398 5-HT6 3.0–3.2 Rat 5-HT7 5.0–5.6 Rat α1 1.0 ' α2 186 β >10,000 Mammal D1 12–18 Human D2 3.0–5.6 Human D3 1.9–4.6 Human D4 0.65 Human D5 9.0 Human H1 0.89–3.8 Human H3 >1,000 Human ' 41 ' M1 11–26 Human M2 28–79 Human M3 22 Human M4 18 Human M5 25 Human σ 603 Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.<unk>  is an antagonist of the following receptors: * 5-HT2, 5-HT6, 5-HT7: antipsychotic effects, sedation/anxiolysis, antidepressant effect, weight gain * D1, D2, D3, D4, D5: antipsychotic effects, sedation, extrapyramidal side effects, prolactin increase, depression, apathy/anhedonia, weight gain * H1: sedation, weight gain * Muscarinic acetylcholine receptors: anticholinergic effects, inhibition of extrapyramidal side effects * α1-Adrenergic: hypotension, sedation, anxiolysis Because of its potent serotonin 5-HT2A and muscarinic acetylcholine receptor antagonism,<unk>  causes relatively mild extrapyramidal symptoms. This is in contrast to most other typical antipsychotics. For this reason,<unk>  has sometimes been described instead as an atypical antipsychotic.<unk>  has also been found to act as FIASMA (functional inhibitor of acid sphingomyelinase). Pharmacokinetics One metabolite of<unk>  is N-desmethylchlorprothixene. none
Chlorprothixene
Mephentermine
Triflupromazine
Alosetron
Etilamfetamine
Acetryptine
Levomepromazine
Beclamide